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Introduction
Abatacept (ABA) - a new generation biological DMARD.
It was approved in Russia in 2009. ABA selectively modu-
lates T-cell activation, which seems to play the key role in
the pathogenesys of Juvenile Idiopathic Arthriris (JIA).
Efficacy and safety of ABA was assessed in AWAIKEN
trial in different types of patients who had polyarticular
course of JIA at the enrollment.
Objectives
This prospective observation was aimed to assess effec-
tiveness and safety of ABA in patients with different
types and clinical variants of active JIA in real clinical
practice.
Methods
30 children with JIA were treated with ABA. 23 (77%) pts
had polyarticular course of JIA and 7 (23%) - systemic
JIA. 11 children were diagnosed with acute uveitis (totally
14 affected eyes). 28 (93%) of pts were female. All
patients had high degree (III) of disease activity. Mean
disease duration was 6,1 ± 3,2 yr. 29 patients previously
had an inadequate response to 2 or more non-biological,
one child with heavy course of systemic JIA was treated
with infliximab during 1 year before starting ABA. Treat-
ment effectiveness was assessed according to the ACR
Pediatric criteria: ACR pedi 30, ACR pedi 50, acrpedi 70,
and ACR pedi 90 after 6 and 12 months of abatacept
therapy. All patients received ABA in dose 10 mg/kg at
day 1, week 2 and 4 and every 4 weeks thereafter.
Results
In the group of pts with systemic JIA after 6 months of
ABA treatment 6 of 7 patients (86%) achieved ACR Pedi
30 response, 5 (71%) - ACR Pedi 50, and 3 (43%) - ACR
Pedi 70. 12 months data was available for 5 patients (others
are still on treatment but less than 12 moths). Four of five
pts (80%) achieved ACR pedi-30, 3(60%) - ACR Pedi 50
response, 2 (40%) ACR pedi 70, and 1 (20%) ACR pedi 90.
In the group of pts with poliarticular course of JIA
treatment effectiveness was assessed in 22 pts. One girl
had experienced an infusion-related reaction (potentially
associated with hypersensitivity) after 3rd infusion and
ABA treatment was stopped. After 6 months 20 of 22 pts
(91%) achieved ACR pedi 30 response, 17 (77%) - ACR
pedi-50, 9 (41%) - ACR pedi-70, 2 (9%) - ACR pedi 90.
14 of 22 patients with polyarticular JIA have completed
12 months of ABA treatment. 12 of them (86%) achieved
ACR pedi 30 response, 11 (78%) - ACR pedi 50, 8 (57%) -
ACR pedi 70 and 2 (14%) - ACR pedi 90. Abatacept also
showed efficacy in treatment of JIA associated uveitis.
After 6 months of treatment the count of affected eyes
was significantly reduced. In 72% of patients complete
remission of uveitis was achieved.
Adverse events were observed in 2 patients (6,7%): 1 case
of infusion related reaction, 1 pts experienced common
Herpes simplex infection (ABA treatment was stopped
after 12 months).
Conclusion
Abatacept have shown its effectiveness in the majority of
patients with long standing JIA (systemic and polyarticular
course) with high disease activity, and inadequate response
to previous treatment with dmards. Better results were
observed in patients with poliarticular JIA.
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